Scleroderma Australia and TrialScreen win GPPS award for putting patients at the center of clinical research
Kuala Lumpur, June 2025
Scleroderma Australia and TrialScreen have been recognized with the Co-Creation and Partnership Award at the Global Patient Partnership Summit (GPPS25) for Scleroderma@ResearchFriends, a national program that makes clinical trials easier to find, understand, and reach for Australians living with scleroderma. The award was accepted by Scleroderma Australia's Deputy Chair, Tara Haneveld, at the summit in Kuala Lumpur.
"Together, we've shown how rare disease communities can lead, from the ground up, and set new global standards for partnership."
Tara Haneveld, Deputy Chair, Scleroderma Australia
Scleroderma@ResearchFriends was built by TrialScreen with the Scleroderma Australia community. It brings current scleroderma trials into one trusted place, branded by Scleroderma Australia, and presents them in plain language so people can check their own fit privately before deciding whether to share any contact details. Community webinars, clinician Q&As, and lived-experience content sit alongside the Scleroderma Trial Finder, so people can learn first and connect only when they are ready. When someone does choose to connect, the introduction is routed through Scleroderma Australia, a partner the community already trusts.
Scleroderma is a rare, complex, and often severe autoimmune condition affecting more than 6,000 Australians. Six scleroderma trials are currently recruiting in Australia, yet many people never hear about them. The barrier is rarely distance or a reluctance to take part. It is the absence of clear, trustworthy information about trials and how they actually work.
The approach is working. Since launching in February 2025, the community has grown from zero to more than 250 research-engaged members. Across a recent two-month period, most people who checked their eligibility and were a good match chose to share their details with a trial site.
The difference shows up in how people describe it. One participant told us that knowing more about research gives them hope. Another reflected that a supportive community and clear language made not qualifying less crushing, while still giving a sense of what might come next.
"This partnership with TrialScreen aligns perfectly with our mission to support and advocate for people living with scleroderma. By combining our strengths, we have created a vibrant ecosystem of engaged research advocates, ultimately improving outcomes for patients across Australia."
Amanda Lawrie-Jones, Chair, Scleroderma Australia
"By joining this community, we put lived experience at the front of research. Growing our health literacy along the way is essential. This means hope can not only survive, but grow."
Tara Haneveld, Deputy Chair, Scleroderma Australia
"Information respects lived experience and avoids spin. People can learn first, self-screen privately, and opt in when ready. They have ongoing community support and clinician access, with honest framing around strict eligibility to reduce disappointment. The program builds trust through access to a wide set of resources, from disease education and specialist connections to a current list of open and upcoming studies."
Emma Burrows, Head of Scientific Engagement, TrialScreen
About Scleroderma Australia
Scleroderma Australia is the national voice for Australians living with scleroderma, uniting state networks and support groups to improve care, connection, and research access.
About TrialScreen
TrialScreen was built to bridge the gap between clinical research and the people who can benefit from it. We are mission-driven to make finding and joining a clinical trial straightforward, transparent, and accessible to everyone. TrialScreen lists every registered clinical trial globally, not just sponsored studies, giving people plain-language information and the ability to check study fit before sharing personal contact details.
About the award
The Co-Creation and Partnership Award was presented at the Global Patient Partnership Summit (GPPS25), hosted by Boehringer Ingelheim and co-designed with a global patient steering committee. The summit brought together patient advocacy leaders from across the Asia-Pacific to embed the patient voice in health innovation.
Learn more
Scleroderma@ResearchFriends: scleroderma.researchfriends.org
Scleroderma Trial Finder: sclerodermaaustralia.trialscreen.org
Media contact
Emma Burrows
Head of Scientific Engagement, TrialScreen
E emma.burrows@trialscreen.com